CFRX: IND Application for CF-370 Submitted to FDA…

Zacks Small Cap Research2023-09-21

By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update IND Application for CF-370 Submitted to FDA On September 18, 2023, ContraFect Corp. (NASDAQ:CFRX) announced that it ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2369816724?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/NvLM7Xvzf0FmLRgtXNC0ug--~B/aD03NTI7dz0xNDE0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/bc0e228483aa1d2b02052804feb4f9c1","is_english":true,"pubTime":"2023-09-21 21:40","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2369816724","market":"us","top_or_hot":-1,"title":"CFRX: IND Application for CF-370 Submitted to FDA…","media":"Zacks Small Cap Research","content":"<div>\n<p>By David Bautz, PhD\n NASDAQ:CFRX\nREAD THE FULL CFRX RESEARCH REPORT\nBusiness Update\nIND Application for CF-370 Submitted to FDA\nOn September 18, 2023, ContraFect Corp. (NASDAQ:CFRX) announced that it ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cfrx-ind-application-cf-370-134000715.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CFRX: IND Application for CF-370 Submitted to FDA…</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCFRX: IND Application for CF-370 Submitted to FDA…\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-09-21 21:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/cfrx-ind-application-cf-370-134000715.html><strong>Zacks Small Cap Research</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By David Bautz, PhD\n NASDAQ:CFRX\nREAD THE FULL CFRX RESEARCH REPORT\nBusiness Update\nIND Application for CF-370 Submitted to FDA\nOn September 18, 2023, ContraFect Corp. (NASDAQ:CFRX) announced that it ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cfrx-ind-application-cf-370-134000715.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/cfrx-ind-application-cf-370-134000715.html","article_id":"2369816724","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/NvLM7Xvzf0FmLRgtXNC0ug--~B/aD03NTI7dz0xNDE0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/bc0e228483aa1d2b02052804feb4f9c1"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2369816724","pubTimestamp":1695303600,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"On September 18, 2023, ContraFect Corp.  announced that it had submitted an Investigational New Drug  application to the U.S. FDA on September 15, 2023 for CF-370 for the treatment of hospital-acquired bacterial pneumonia  and ventilator-associated bacterial pneumonia . The FDA has 30 days to respond if additional information is required, however if the agency does not have comments or concerns then after 30 days ContraFect is eligible to begin a clinical trial. A first-in-human trial could begin as early as the fourth quarter of 2023, assuming the FDA doesn’t require any additional information for the IND.The following slide gives an overview of the planned early stage clinical trials for CF-370. The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics of CF-370 in healthy adult subjects through both a single ascending dose  and multiple ascending dose  trial. There will also be an evaluation of the lung concentration of CF-370 through bronchoalveolar lavage.DISC","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4588":"碎股","BK4093":"化肥与农用药剂","CDC":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","BK4585":"ETF&股票定投概念","CF":"CF工业"},"translate_title":"CFRX：向FDA提交CF-370的IND申请…","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDC":1,"CF":1,"CFRX":1},"content_text":"By David Bautz, PhD\n NASDAQ:CFRX\nREAD THE FULL CFRX RESEARCH REPORT\nBusiness Update\nIND Application for CF-370 Submitted to FDA\nOn September 18, 2023, ContraFect Corp. (NASDAQ:CFRX) announced that it had submitted an Investigational New Drug (IND) application to the U.S. FDA on September 15, 2023 for CF-370 for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). The FDA has 30 days to respond if additional information is required, however if the agency does not have comments or concerns then after 30 days ContraFect is eligible to begin a clinical trial. A first-in-human trial could begin as early as the fourth quarter of 2023, assuming the FDA doesn’t require any additional information for the IND. \nThe following slide gives an overview of the planned early stage clinical trials for CF-370. The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics of CF-370 in healthy adult subjects through both a single ascending dose (SAD) and multiple ascending dose (MAD) trial. There will also be an evaluation of the lung concentration of CF-370 through bronchoalveolar lavage. \n\nHABP/VABP are serious and potentially life-threatening infections that have a high mortality rate. They are currently the most common type of hospital-acquired infections in acute care hospitals and are a significant issue for patients in the intensive care unit (CDC). A recent study of 17,819 patients across 253 acute care hospitals showed that the mortality rates for ventilated hospital-acquired pneumonia, ventilator-associated pneumonia, and non-ventilated hospital-acquired pneumonia were 29%, 21%, and 12%, respectively (Zilberberg et al., 2022). The most commonly implicated Gram-negative pathogens in HABP/VABP are Pseudomonas aeruginosa, Acinetobacter species, Klebsiella species, Escherichia coli, and Enterobacter cloacae. Many of these species are multi-drug resistant (MDR) or extensively-drug resistant (XDR), making the infections all the more difficult to treat while resulting in a heavy economic burden. The estimated median total hospital cost for ventilator-associated pneumonia patients is $77,657.\nConclusion\nThe IND submission for CF-370 is a great milestone for ContraFect as the company continues to execute on its business plan. We look forward to additional updates regarding the upcoming Phase 1 study of CF-370, which we currently estimate could begin in the fourth quarter of 2023, assuming the FDA does not request any additional information for the IND submission. With no changes to our model our valuation remains at $7.00 per share. \nSUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. \n \nDISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2369816724"}